AI Summary & Key Takeaways
AI InsightTherefore, it might be the modality of choice for patients with suspicion for metastatic disease,despite negative bone scan and conventional imaging results.
📌 3 Key Takeaways
Abstract
Background/aim: The aim of our study was to compare Tc-99m MDP bone scan and Ga-68 PSMA PET/CT in terms of detection ofbone metastasis in prostate cancer patients.Materials and methods: A total of 28 prostate cancer patients with bone scan and PSMA PET/CT performed within 90 days wereretrospectively included in our analysis. All bone lesions were scored as negative (score-0), positive (score-1), or suspicious (score-2) formetastasis by two experienced nuclear medicine physicians. Both patient-based and region-based analyses were made for all osseouslesions.Results: On per-patient analysis; sensitivity, specificity, positive predictive value (PPV), negative predictive value (NPV), and accuracywere 72.7%, 52.9%, 50%, 75%, and 60.7%, respectively, for bone scan and 90.9%, 100%, 100%, 94.4%, and 96.4%, respectively, forPSMA PET/CT. On per-region analysis; sensitivity, specificity, PPV, NPV, and accuracy were 76.2%, 80.9%, 57.1%, 91.1%, and 79.8%,respectively, for bone scan and 85.7%, 100%, 100%, 95.5%, and 95.4%, respectively, for PSMA PET/CT.Conclusion: Ga-68 PSMA PET/CT has higher sensitivity, specificity, and accuracy compared to bone scan in terms of bone metastasisdetection in prostate cancer patients. Therefore, it might be the modality of choice for patients with suspicion for metastatic disease,despite negative bone scan and conventional imaging results.